




EMLc
ATC codes: [J04BA01](#)

Indication	Leprosy <span>ICD11 code: <a href="#">1B50.Z</a></span>
INN	Clofazimine
Medicine type	Chemical agent
List type	Core (EML) (EMLc)
Additional notes	Medicines used in the treatment of leprosy should never be used except in combination. Combination therapy is essential to prevent the emergence of drug resistance. Colour-coded blister packs (MDT blister packs) containing standard two-medicine (paucibacillary leprosy) or three-medicine (multibacillary leprosy) combinations for adult and childhood leprosy should be used. MDT blister packs can be supplied free of charge through WHO.
Formulations	Oral > Solid: 100 mg ; 50 mg
EML status history	First added in 1977 ( <a href="#">TRS 615</a> ) Changed in 1982 ( <a href="#">TRS 685</a> ) Changed in 1984 ( <a href="#">TRS 722</a> ) Changed in 2003 ( <a href="#">TRS 920</a> ) Changed in 2007 ( <a href="#">TRS 946</a> ) Changed in 2019 ( <a href="#">TRS 1021</a> )
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 
Wikipedia	<a href="#">Clofazimine</a> 
DrugBank	<a href="#">Clofazimine</a> 

## Summary of evidence and Expert Committee recommendations

The Expert Committee recommended an amendment to the dosage form terminology for clofazimine, replacing 'capsule' with 'solid oral dosage form'.

